RevMed’s Rasonque gets a subtype data asterisk, but analysts remain bullish

Data released by the FDA show that Revolution Medicine’s newly approved pancreatic cancer drug underperformed in a large subgroup of patients, but analysts say the biotech still has a clear winner.